vs
Side-by-side financial comparison of Agilent Technologies (A) and Aclaris Therapeutics, Inc. (ACRS). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.3M, roughly 1388.4× Aclaris Therapeutics, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs -1528.6%, a 1545.5% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs -85.9%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $-13.2M). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs -26.5%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
A vs ACRS — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.3M |
| Net Profit | $305.0M | $-19.8M |
| Gross Margin | 52.6% | 58.9% |
| Operating Margin | 19.6% | -1755.5% |
| Net Margin | 17.0% | -1528.6% |
| Revenue YoY | 7.0% | -85.9% |
| Net Profit YoY | -4.1% | 79.5% |
| EPS (diluted) | $1.07 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.3M | ||
| Q3 25 | $1.7B | $3.3M | ||
| Q2 25 | $1.7B | $1.8M | ||
| Q1 25 | $1.7B | $1.5M | ||
| Q4 24 | $1.7B | $9.2M | ||
| Q3 24 | $1.6B | $4.3M | ||
| Q2 24 | $1.6B | $2.8M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-19.8M | ||
| Q3 25 | $336.0M | $-14.6M | ||
| Q2 25 | $215.0M | $-15.4M | ||
| Q1 25 | $318.0M | $-15.1M | ||
| Q4 24 | $351.0M | $-96.6M | ||
| Q3 24 | $282.0M | $-7.6M | ||
| Q2 24 | $308.0M | $-11.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 58.9% | ||
| Q3 25 | 51.1% | 83.7% | ||
| Q2 25 | 51.9% | 71.0% | ||
| Q1 25 | 53.5% | 65.2% | ||
| Q4 24 | 53.9% | 92.3% | ||
| Q3 24 | 54.2% | 85.0% | ||
| Q2 24 | 54.4% | 77.4% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -1755.5% | ||
| Q3 25 | 20.7% | -519.8% | ||
| Q2 25 | 18.0% | -1035.9% | ||
| Q1 25 | 22.4% | -1242.9% | ||
| Q4 24 | 24.0% | -1082.3% | ||
| Q3 24 | 21.1% | -240.9% | ||
| Q2 24 | 23.1% | -464.7% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -1528.6% | ||
| Q3 25 | 19.3% | -443.0% | ||
| Q2 25 | 12.9% | -868.3% | ||
| Q1 25 | 18.9% | -1036.8% | ||
| Q4 24 | 20.6% | -1048.3% | ||
| Q3 24 | 17.9% | -174.6% | ||
| Q2 24 | 19.6% | -397.2% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.16 | ||
| Q3 25 | $1.18 | $-0.12 | ||
| Q2 25 | $0.75 | $-0.13 | ||
| Q1 25 | $1.11 | $-0.12 | ||
| Q4 24 | $1.23 | $-1.21 | ||
| Q3 24 | $0.97 | $-0.11 | ||
| Q2 24 | $1.05 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $20.0M |
| Total DebtLower is stronger | $3.0B | — |
| Stockholders' EquityBook value | $6.9B | $103.1M |
| Total Assets | $12.8B | $160.5M |
| Debt / EquityLower = less leverage | 0.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $20.0M | ||
| Q3 25 | $1.5B | $25.3M | ||
| Q2 25 | $1.5B | $25.4M | ||
| Q1 25 | $1.5B | $30.4M | ||
| Q4 24 | $1.3B | $24.6M | ||
| Q3 24 | $1.8B | $47.7M | ||
| Q2 24 | $1.7B | $22.8M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $103.1M | ||
| Q3 25 | $6.4B | $120.1M | ||
| Q2 25 | $6.1B | $131.7M | ||
| Q1 25 | $6.0B | $144.1M | ||
| Q4 24 | $5.9B | $155.6M | ||
| Q3 24 | $5.9B | $130.2M | ||
| Q2 24 | $6.2B | $133.8M |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $160.5M | ||
| Q3 25 | $12.2B | $175.5M | ||
| Q2 25 | $12.2B | $189.1M | ||
| Q1 25 | $11.9B | $198.1M | ||
| Q4 24 | $11.8B | $220.3M | ||
| Q3 24 | $11.0B | $182.4M | ||
| Q2 24 | $10.9B | $161.1M |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $-13.1M |
| Free Cash FlowOCF − Capex | $175.0M | $-13.2M |
| FCF MarginFCF / Revenue | 9.7% | -1015.8% |
| Capex IntensityCapex / Revenue | 5.2% | 1.9% |
| Cash ConversionOCF / Net Profit | 0.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $-47.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-13.1M | ||
| Q3 25 | $362.0M | $-10.9M | ||
| Q2 25 | $221.0M | $-10.0M | ||
| Q1 25 | $431.0M | $-13.1M | ||
| Q4 24 | $481.0M | $-8.9M | ||
| Q3 24 | $452.0M | $22.0M | ||
| Q2 24 | $333.0M | $-12.3M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-13.2M | ||
| Q3 25 | $259.0M | $-11.0M | ||
| Q2 25 | $107.0M | $-10.0M | ||
| Q1 25 | $334.0M | $-13.1M | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | $-12.3M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -1015.8% | ||
| Q3 25 | 14.9% | -332.1% | ||
| Q2 25 | 6.4% | -563.5% | ||
| Q1 25 | 19.9% | -900.3% | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | -446.0% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 1.9% | ||
| Q3 25 | 5.9% | 0.7% | ||
| Q2 25 | 6.8% | 1.2% | ||
| Q1 25 | 5.8% | 3.0% | ||
| Q4 24 | 5.5% | 0.0% | ||
| Q3 24 | 5.8% | 0.0% | ||
| Q2 24 | 6.5% | 0.5% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ACRS
Segment breakdown not available.
